FIELD: chemistry.
SUBSTANCE: invention relates to compounds of formula I or stereoisomers, tautomers or pharmaceutically acceptable salts thereof, in which ring A, ring C and X are as defined herein. 
.
EFFECT: compounds of formula I are TrkA kinase inhibitors and are useful for the treatment of diseases that can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation / inflammatory diseases, neurodegenerative diseases, some infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.
35 cl, 7 tbl, 160 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PYRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS AS TRKA KINASE INHIBITORS | 2012 |
|
RU2606131C2 |
| SUBSTITUTED COMPOUNDS OF PYRAZOLE[1,5-a]PYRIMIDINE AS TRK KINASE INHIBITORS | 2010 |
|
RU2584157C2 |
| N-PYRROLIDINYL-UREA, N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | 2013 |
|
RU2677667C2 |
| 1-((3S,4R)-4-(3-FLUOROPHENYL)-1-(2-METHOXYETHYL)PYRROLIDIN-3-YL)-3-(4-METHYL-3-(2-METHYLPYRIMIDIN-5-YL)-1-PHENYL-1N-PYRAZOL-5-YL)UREA AS A TRKA KINASE INHIBITOR | 2015 |
|
RU2719489C2 |
| SUBSTITUTED N-(1H-INDAZOLE-4-YL) IMIDAZOLE [1,2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE TYPE III RECEPTOR | 2011 |
|
RU2591195C2 |
| TRIAZOLOPYRINE COMPOUNDS AS KINASE INHIBITORS PIM | 2012 |
|
RU2598846C2 |
| COMPOUNDS OF SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZOL [1,2-a]-3-CARBOXAMIDE AS cFMS INHIBITORS | 2010 |
|
RU2562977C2 |
| PROPOSED 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | 2022 |
|
RU2826000C1 |
| SULPHONYLUREAS AND RELATED COMPOUNDS AND THEIR USE | 2016 |
|
RU2795512C2 |
| N-ACYL-N'-(PYRIDIN-2-YL)CARBAMIDES AND THEIR ANALOGUES EXHIBITING ANTICANCER AND ANTIPROLIFERATIVE ACTIVITY | 2014 |
|
RU2769607C2 |
